2.5 mg semaglutide to tirzepatide and key differences, weight loss results (2026) How to choose between semaglutide
Description
What the 2025 Gastroenterology Metaanalysis Found The systematic review and metaanalysis (DOI: 10.1053/j.gastro.2025.06.003) evaluated safety outcomes across randomized trials and realworld studies of GLP1 RAs
CNNs Erin Burnett speaks to Eli Lilly CEO David Ricks on major changes to weight-loss drugs and expanded manufacturing
GLP-1s are no longer the "future" of diabetes care. They're the present now that 23% of first-line diabetes treatment are GLP-1s
Guidance on how to properly take and manage GLP-1 medications in everyday use, covering timing, adjustments, and safe day-to-day treatment practices.
